Smigan L, Bucht G, von Knorring L, Perris C, Wahlin A
Neuropsychobiology. 1984;11(1):33-8. doi: 10.1159/000118047.
Renal functions were examined in 53 patients before the start of long-term lithium treatment (I) and then after 4 months (II) and 12 months (III) on lithium treatment. The tubular function was studied by means of the DDAVP (Minirin) test and the glomerular filtration rate was measured by creatinine clearance. The mean maximum urine osmolality (+/- SE) on the first occasion (I) was 800 +/- 20 mosm/kg H2O, 702 +/- 20 on the second (II), and on the third (III) 723 +/- 17 mosm/kg H2O. The mean creatinine clearance before the start of lithium treatment (I) was 128 +/- 5 ml/min, after 4 months (II) 106 +/- 4 and after 12 months (III) 114 +/- 5 ml/min. The results of the present study suggest that lithium treatment with serum levels of approximately 0.6 mmol/l causes a decrease in renal concentrating ability and the glomerular filtration rate in the early stages after the start of therapy. This decrease in the renal functions does not seem to progress during the first year of lithium treatment.
对53例患者在长期锂治疗开始前（I）、锂治疗4个月后（II）以及12个月后（III）进行了肾功能检查。通过去氨加压素（弥凝）试验研究肾小管功能，通过肌酐清除率测量肾小球滤过率。首次检查（I）时平均最大尿渗透压（±标准误）为800±20 mosm/kg H₂O，第二次（II）为702±20，第三次（III）为723±17 mosm/kg H₂O。锂治疗开始前（I）平均肌酐清除率为128±5 ml/min，4个月后（II）为106±4，12个月后（III）为114±5 ml/min。本研究结果表明，血清锂水平约为0.6 mmol/l的锂治疗在治疗开始后的早期会导致肾脏浓缩能力和肾小球滤过率下降。在锂治疗的第一年，肾功能的这种下降似乎不会进展。
